Gin Hwa Biotech (ROCO:7806) Total Current Liabilities: NT$173.6 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7806 Gin Hwa Biotech Inc ROCO:7806
22 GF Score
Price NT$61.90
! 2 Warning Signs
View Full Analysis

What is Gin Hwa Biotech Total Current Liabilities?

Gin Hwa Biotech ROCO:7806 22 Total Current Liabilities is NT$173.6 Mil as of Dec. 2025. GuruFocus rates ROCO:7806 with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Gin Hwa Biotech's total current liabilities for the quarter that ended in Dec. 2025 was NT$173.6

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Gin Hwa Biotech Total Current Liabilities Related Terms

Gin Hwa Biotech Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Gin Hwa Biotech's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gin Hwa Biotech Total Current Liabilities Chart

Gin Hwa Biotech Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Current Liabilities
96.46 207.65 115.18 173.59

Gin Hwa Biotech Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Current Liabilities Get a 7-Day Free Trial 207.65 203.26 115.18 196.50 173.59
ROCO:7806
22GF Score
Gin Hwa Biotech Inc ROCO:7806
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gin Hwa Biotech Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Gin Hwa Biotech's Total Current Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=89.171+71.929
+Other Current Liabilities+Current Deferred Liabilities
=12.491+0
=173.6

Gin Hwa Biotech's Total Current Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=89.171+71.929
+Other Current Liabilities+Current Deferred Liabilities
=12.491+0
=173.6

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of NT$173.6 Mil mean?
Gin Hwa Biotech (ROCO:7806) has a Total Current Liabilities of NT$173.6 Mil as of Dec. 2025. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Gin Hwa Biotech and its competitors.
Is Gin Hwa Biotech's Total Current Liabilities too high?
Gin Hwa Biotech's current Total Current Liabilities is NT$173.6 Mil. Overall, Gin Hwa Biotech has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Gin Hwa Biotech's Total Current Liabilities compare to VRTX and REGN?
Gin Hwa Biotech's Total Current Liabilities of NT$173.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Biotechnology company?
A good Total Current Liabilities depends on the Biotechnology industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Gin Hwa Biotech and its competitors. Gin Hwa Biotech's current Total Current Liabilities is NT$173.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gin Hwa Biotech stock overvalued right now?
Gin Hwa Biotech (ROCO:7806) has a current Total Current Liabilities of NT$173.6 Mil. The current Total Current Liabilities is NT$173.6 Mil. Gin Hwa Biotech's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Gin Hwa Biotech (ROCO:7806), the current Total Current Liabilities is NT$173.6 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gin Hwa Biotech Business Description

Address No. 5, Guangming 7th Lane, Weixin Road, 1st Floor, Yong'an District, Kaohsiung, TWN, 828
Gin Hwa Biotech Inc is engaged in developing completely original products to achieve every vision. Its Services and technology are Product Development, OEM Service, Core Technology, R & D Center, Professional Production, and Others.
22GF Score

Get the complete analysis for ROCO:7806

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$61.90
Price